Research statistics

Triptorelin research: publications and trials

What has been published on Triptorelin: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Triptorelin works or is safe. For what it is and what the studies found, see the Triptorelin profile.
Automated weekly refresh · data through November 1, 2026

At a glance

Publications, all years

1,670

Since 1980

Publications in 2026 so far

29

Through November 1, 2026

Human clinical research

69.6%

1,152 of 1,655 classified

Registered clinical trials

200

ClinicalTrials.gov

Randomized controlled trials

270

Publications reporting an RCT in people

Systematic reviews and meta-analyses

9

Preclinical studies

25.3%

303 animal · 106 in vitro · 10 computational

Records that only mention it

830

Not counted above

Status in the library: FDA-approved. 15 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Triptorelin publications by year and evidence

1980, Human clinical research: 2 of 61980, Preclinical (animal, in vitro, computational): 4 of 61981, Human clinical research: 10 of 171981, Preclinical (animal, in vitro, computational): 7 of 171982, Human clinical research: 7 of 101982, Preclinical (animal, in vitro, computational): 3 of 101983, Human clinical research: 5 of 101983, Preclinical (animal, in vitro, computational): 5 of 101984, Human clinical research: 17 of 271984, Preclinical (animal, in vitro, computational): 10 of 271985, Human clinical research: 12 of 291985, Preclinical (animal, in vitro, computational): 17 of 291986, Human clinical research: 25 of 321986, Preclinical (animal, in vitro, computational): 6 of 321986, Reviews and meta-analyses: 1 of 321987, Human clinical research: 17 of 311987, Preclinical (animal, in vitro, computational): 11 of 311987, Other and not yet classified: 3 of 311988, Human clinical research: 32 of 491988, Preclinical (animal, in vitro, computational): 11 of 491988, Reviews and meta-analyses: 2 of 491988, Other and not yet classified: 4 of 491989, Human clinical research: 29 of 441989, Preclinical (animal, in vitro, computational): 13 of 441989, Reviews and meta-analyses: 1 of 441989, Other and not yet classified: 1 of 441990, Human clinical research: 22 of 361990, Preclinical (animal, in vitro, computational): 13 of 361990, Other and not yet classified: 1 of 361991, Human clinical research: 26 of 381991, Preclinical (animal, in vitro, computational): 12 of 381992, Human clinical research: 30 of 441992, Preclinical (animal, in vitro, computational): 14 of 441993, Human clinical research: 42 of 551993, Preclinical (animal, in vitro, computational): 13 of 551994, Human clinical research: 44 of 531994, Preclinical (animal, in vitro, computational): 7 of 531994, Reviews and meta-analyses: 1 of 531994, Other and not yet classified: 1 of 531995, Human clinical research: 36 of 391995, Preclinical (animal, in vitro, computational): 3 of 391996, Human clinical research: 38 of 461996, Preclinical (animal, in vitro, computational): 8 of 461997, Human clinical research: 27 of 331997, Preclinical (animal, in vitro, computational): 5 of 331997, Other and not yet classified: 1 of 331998, Human clinical research: 34 of 451998, Preclinical (animal, in vitro, computational): 10 of 451998, Reviews and meta-analyses: 1 of 451999, Human clinical research: 26 of 331999, Preclinical (animal, in vitro, computational): 7 of 332000, Human clinical research: 35 of 442000, Preclinical (animal, in vitro, computational): 7 of 442000, Reviews and meta-analyses: 1 of 442000, Other and not yet classified: 1 of 442001, Human clinical research: 27 of 442001, Preclinical (animal, in vitro, computational): 13 of 442001, Reviews and meta-analyses: 1 of 442001, Other and not yet classified: 3 of 442002, Human clinical research: 19 of 352002, Preclinical (animal, in vitro, computational): 14 of 352002, Reviews and meta-analyses: 1 of 352002, Other and not yet classified: 1 of 352003, Human clinical research: 24 of 352003, Preclinical (animal, in vitro, computational): 7 of 352003, Reviews and meta-analyses: 2 of 352003, Other and not yet classified: 2 of 352004, Human clinical research: 23 of 392004, Preclinical (animal, in vitro, computational): 12 of 392004, Reviews and meta-analyses: 1 of 392004, Other and not yet classified: 3 of 392005, Human clinical research: 24 of 382005, Preclinical (animal, in vitro, computational): 10 of 382005, Reviews and meta-analyses: 4 of 382006, Human clinical research: 30 of 422006, Preclinical (animal, in vitro, computational): 9 of 422006, Reviews and meta-analyses: 1 of 422006, Other and not yet classified: 2 of 422007, Human clinical research: 24 of 282007, Preclinical (animal, in vitro, computational): 3 of 282007, Reviews and meta-analyses: 1 of 282008, Human clinical research: 25 of 402008, Preclinical (animal, in vitro, computational): 14 of 402008, Other and not yet classified: 1 of 402009, Human clinical research: 25 of 342009, Preclinical (animal, in vitro, computational): 8 of 342009, Reviews and meta-analyses: 1 of 342010, Human clinical research: 18 of 302010, Preclinical (animal, in vitro, computational): 7 of 302010, Reviews and meta-analyses: 4 of 302010, Other and not yet classified: 1 of 302011, Human clinical research: 21 of 322011, Preclinical (animal, in vitro, computational): 7 of 322011, Reviews and meta-analyses: 1 of 322011, Other and not yet classified: 3 of 322012, Human clinical research: 33 of 462012, Preclinical (animal, in vitro, computational): 12 of 462012, Other and not yet classified: 1 of 462013, Human clinical research: 21 of 282013, Preclinical (animal, in vitro, computational): 5 of 282013, Reviews and meta-analyses: 1 of 282013, Other and not yet classified: 1 of 282014, Human clinical research: 19 of 312014, Preclinical (animal, in vitro, computational): 10 of 312014, Reviews and meta-analyses: 1 of 312014, Other and not yet classified: 1 of 312015, Human clinical research: 35 of 522015, Preclinical (animal, in vitro, computational): 12 of 522015, Reviews and meta-analyses: 4 of 522015, Other and not yet classified: 1 of 522016, Human clinical research: 30 of 442016, Preclinical (animal, in vitro, computational): 10 of 442016, Reviews and meta-analyses: 4 of 442017, Human clinical research: 16 of 292017, Preclinical (animal, in vitro, computational): 9 of 292017, Reviews and meta-analyses: 3 of 292017, Other and not yet classified: 1 of 292018, Human clinical research: 28 of 462018, Preclinical (animal, in vitro, computational): 12 of 462018, Reviews and meta-analyses: 5 of 462018, Other and not yet classified: 1 of 462019, Human clinical research: 26 of 362019, Preclinical (animal, in vitro, computational): 8 of 362019, Reviews and meta-analyses: 2 of 362020, Human clinical research: 31 of 382020, Preclinical (animal, in vitro, computational): 7 of 382021, Human clinical research: 24 of 342021, Preclinical (animal, in vitro, computational): 7 of 342021, Reviews and meta-analyses: 2 of 342021, Other and not yet classified: 1 of 342022, Human clinical research: 19 of 292022, Preclinical (animal, in vitro, computational): 7 of 292022, Reviews and meta-analyses: 1 of 292022, Other and not yet classified: 2 of 292023, Human clinical research: 19 of 272023, Preclinical (animal, in vitro, computational): 4 of 272023, Reviews and meta-analyses: 4 of 272024, Human clinical research: 30 of 382024, Preclinical (animal, in vitro, computational): 7 of 382024, Other and not yet classified: 1 of 382025, Human clinical research: 27 of 452025, Preclinical (animal, in vitro, computational): 11 of 452025, Reviews and meta-analyses: 4 of 452025, Other and not yet classified: 3 of 452026 (to date), Human clinical research: 18 of 292026 (to date), Preclinical (animal, in vitro, computational): 8 of 292026 (to date), Reviews and meta-analyses: 3 of 29Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified020406019801990200020102026*
Counted PubMed publications by year of first publication. * 2026 runs to November 1, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
198024006
19811070017
1982730010
1983550010
198417100027
198512170029
19862561032
198717110331
198832112449
198929131144
199022130136
199126120038
199230140044
199342130055
19944471153
19953630039
19963880046
19972750133
199834101045
19992670033
20003571144
200127131344
200219141135
20032472235
200423121339
200524104038
20063091242
20072431028
200825140140
20092581034
20101874130
20112171332
201233120146
20132151128
201419101131
201535124152
201630104044
20171693129
201828125146
20192682036
20203170038
20212472134
20221971229
20231944027
20243070138
202527114345
2026 (to date)1883029

Study types

Other clinical trial418
Observational human study309
Animal study303
Randomized controlled trial270
Case report155
In vitro study106
Review49
Editorial, letter or other26
Not yet classified15
Computational study10
Systematic review5
Meta-analysis4

Research areas

From MeSH major topics. A paper can be in several areas.

Reproductive and sexual health1,028
Endocrinology843
Oncology578
Neurological and mental health163
Dermatology91
Musculoskeletal71
Immune system41
Metabolic health41
Gastrointestinal32
Cardiovascular29
Obesity and weight management25
Longevity and aging15

Registered clinical trials

38 of 87 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 90 · Unknown status: 56 · Recruiting: 27 · Terminated: 12 · Active, not recruiting: 8 · Withdrawn: 5 · Not yet recruiting: 2
Early phase 1: 1 · Phase not applicable: 47 · Phase 1: 2 · Phase 1 / Phase 2: 2 · Phase 2: 38 · Phase 2 / Phase 3: 9 · Phase 3: 54 · Phase 4: 47

TrialStatusPhaseStartedResults
Intranasal Nafarelin For Triggering Oocyte MaturationNCT06763926 · 154 enrolledRecruitingPhase 42026-10—
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNCT07782840 · 40 enrolledNot yet recruitingPhase 22026-10—
Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal RespondersNCT07861399 · 100 enrolledRecruitingPhase not applicable2026-09—
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerNCT07751133 · 1,500 enrolledRecruitingPhase 32026-08—
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTNCT07455903 · 50 enrolledRecruitingPhase 22026-07—
Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseNCT07142551 · 60 enrolledRecruitingPhase 22026-03—
COMPASS - COpenhagen MenoPAuSe StudyNCT07254429 · 192 enrolledRecruitingPhase 22025-10—
The COSMYC Trial (COmbined Suppression of MYC)NCT06922318 · 50 enrolledRecruitingPhase 22025-08—
Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating EndometriosisNCT07696351 · 120 enrolledRecruitingPhase 42025-08—
Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate CancerNCT06795178WithdrawnPhase 32025-07—
Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate CancerNCT06795191WithdrawnPhase 32025-06—
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerNCT06528210WithdrawnPhase 22025-04—
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With CancerNCT06513962 · 60 enrolledRecruitingPhase 32025-02—
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate CancerNCT06734130 · 25 enrolledActive, not recruitingPhase 22025-01—
Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)NCT07816562 · 126 enrolledRecruitingPhase 32024-09—
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer PatientsNCT06225284 · 124 enrolledRecruitingPhase 22024-08—
Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPPNCT06487143 · 134 enrolledNot yet recruitingPhase 42024-07—
Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI CyclesNCT06150703 · 652 enrolledRecruitingPhase 32024-06—
Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained InfertilityNCT06481696 · 90 enrolledUnknown statusPhase not applicable2024-06—
Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist TreatmentNCT07128394 · 590 enrolledRecruitingPhase not applicable2024-02—
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerNCT05896566 · 231 enrolledCompletedPhase 22024-01—
Effect GnRH Agonist Administration in Endometriosis Cyst PatientsNCT06525155 · 32 enrolledRecruitingPhase 32024-01—
Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst TransferNCT06581679 · 184 enrolledCompletedPhase not applicable2023-12—
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersNCT06282588 · 493 enrolledRecruitingPhase 2, Phase 32023-12—
Dose Escalation For INtraprostatic LEsionsNCT05851547 · 54 enrolledRecruitingPhase 22023-11—
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerNCT06059118 · 50 enrolledRecruitingPhase 22023-10—
Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection OutcomesNCT05972902 · 387 enrolledUnknown statusPhase 32023-07—
Use of GnRHa During Chemotherapy for Fertility ProtectionNCT05328258 · 500 enrolledRecruitingPhase 32023-03—
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624NCT05781217 · 534 enrolledRecruitingPhase 32023-03—
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007 · 1,083 enrolledCompletedPhase not applicable2023-02Posted
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerNCT05982093 · 96 enrolledRecruitingPhase 22023-02—
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene AlterationsNCT05498272 · 32 enrolledActive, not recruitingPhase 22023-02—
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the ProstateNCT05590793 · 195 enrolledCompletedPhase 32022-11Posted
DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte MaturationNCT04616729 · 30 enrolledUnknown statusPhase 1, Phase 22022-11—
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the ProstateNCT05458856 · 147 enrolledCompletedPhase 32022-08Posted
Triptorelin for Early Diagnosis of Hypogonadotrophic HypogonadismNCT06691815 · 48 enrolledUnknown statusPhase not applicable2022-08—
COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLESNCT05397795 · 160 enrolledUnknown statusPhase 32022-06—
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerNCT05212857 · 160 enrolledUnknown statusPhase 22022-04—
Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase SupportNCT05286554 · 75 enrolledCompletedPhase 42022-03—
Comparison of Triggers in Double Ovarian Stimulation (DuoStim).NCT05321511 · 165 enrolledUnknown statusPhase 42022-03—
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerNCT05189457 · 32 enrolledActive, not recruitingPhase 22022-01—
Long-term Use of Mifepristone in the Treatment of AdenomyosisNCT05151016 · 140 enrolledUnknown statusEarly phase 12021-12—
Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI CyclesNCT05112692 · 200 enrolledUnknown statusPhase not applicable2021-11—
SRT Versus SRT+ADT in Prostate CancerNCT05019846 · 310 enrolledRecruitingPhase 32021-09—
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.NCT05029622 · 66 enrolledCompletedPhase 32021-08Posted
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerNCT04787744 · 378 enrolledActive, not recruitingPhase 2, Phase 32021-07—
HCG Levels After Ovulation Triggering as Predictors of ICSI OutcomeNCT05969834 · 100 enrolledCompletedPhase not applicable2021-03—
Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.NCT04736602 · 32 enrolledCompletedPhase 32021-03Posted
Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or AdenomyosisNCT04356664 · 180 enrolledRecruitingPhase 2, Phase 32021-03—
Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic GonadotroipinNCT04749979 · 100 enrolledUnknown statusPhase not applicable2021-02—

The 50 most recently started of 200 trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Effects of fixed-time artificial insemination using triptorelin on the reproductive performance of pigs: a meta-analysis.

    Animal : an international journal of animal bioscience · December 20, 2019 · Meta-analysis · cited 7 times · open access

    PMID 31858952 · DOI 10.1017/s1751731119003008 · Reviews and meta-analyses

  2. GnRH analog is ineffective in increasing adult height in girls with puberty onset after 7 years of age: a systematic review and meta-analysis.

    European journal of endocrinology · December 1, 2018 · Meta-analysis · cited 28 times

    PMID 30324797 · DOI 10.1530/eje-18-0473 · Reviews and meta-analyses

  3. Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation .

    Hormone research in paediatrics · March 23, 2017 · Meta-analysis · cited 23 times

    PMID 28334719 · DOI 10.1159/000456545 · Reviews and meta-analyses

  4. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis.

    Reproductive biology and endocrinology : RB&E · September 8, 2010 · Meta-analysis · cited 63 times · open access

    PMID 20825643 · DOI 10.1186/1477-7827-8-107 · Reviews and meta-analyses

  5. Effectiveness and Safety of Postoperative Medical Treatments Following Fertility-Preserving Surgery for Endometriosis: A Network Meta-Analysis.

    BJOG : an international journal of obstetrics and gynaecology · September 29, 2025 · Systematic review · cited 3 times

    PMID 41017486 · DOI 10.1111/1471-0528.70016 · Reviews and meta-analyses

  6. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.

    BJU international · May 8, 2018 · Systematic review · cited 34 times

    PMID 29438592 · DOI 10.1111/bju.14168 · Reviews and meta-analyses

  7. Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

    PharmacoEconomics · July 1, 2017 · Systematic review · cited 16 times

    PMID 27943135 · DOI 10.1007/s40273-016-0481-1 · Reviews and meta-analyses

  8. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.

    The Cochrane database of systematic reviews · June 29, 2016 · Systematic review · cited 9 times · open access

    PMID 27356090 · DOI 10.1002/14651858.cd011322.pub2 · Reviews and meta-analyses

  9. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review.

    The Journal of clinical psychiatry · August 1, 2003 · Systematic review · cited 134 times

    PMID 12927003 · DOI 10.4088/jcp.v64n0806 · Reviews and meta-analyses

  10. The two-shot protocol. A randomized controlled trial of a novel two-injection ovarian stimulation strategy.

    Human reproduction (Oxford, England) · September 25, 2026 · Randomized controlled trial · cited 0 times

    PMID 42786378 · DOI 10.1093/humrep/deag142 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

    Proceedings of the National Academy of Sciences of the United States of America · March 1, 1982 · Other clinical trial · cited 368 times · open access

    PMID 6461861 · DOI 10.1073/pnas.79.5.1658 · Human clinical research

  2. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.

    JAMA · July 1, 2011 · Randomized controlled trial · cited 351 times

    PMID 21771987 · DOI 10.1001/jama.2011.991 · Human clinical research

  3. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.

    The Journal of clinical endocrinology and metabolism · February 1, 2002 · Randomized controlled trial · cited 343 times · open access

    PMID 11836309 · DOI 10.1210/jcem.87.2.8197 · Human clinical research

  4. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.

    The Lancet. Oncology · October 1, 2020 · Randomized controlled trial · cited 329 times · open access

    PMID 33002438 · DOI 10.1016/s1470-2045(20)30454-x · Human clinical research

  5. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.

    Human reproduction (Oxford, England) · June 24, 2005 · Randomized controlled trial · cited 322 times · open access

    PMID 15979994 · DOI 10.1093/humrep/dei150 · Human clinical research

Latest publications

  1. Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study.

    Urologic oncology · October 18, 2026 · Observational human study · cited 0 times

    PMID 42892580 · DOI 10.1016/j.urolonc.2026.09.012 · Human clinical research

  2. Is there a difference in ovarian hyperstimulation syndrome rates in freeze-all treatment cycles in high-risk patients treated with different GnRH agonist triggers?

    Human fertility (Cambridge, England) · October 5, 2026 · Observational human study · cited 0 times · open access

    PMID 42831293 · DOI 10.1080/14647273.2026.2733078 · Human clinical research

  3. The two-shot protocol. A randomized controlled trial of a novel two-injection ovarian stimulation strategy.

    Human reproduction (Oxford, England) · September 25, 2026 · Randomized controlled trial · cited 0 times

    PMID 42786378 · DOI 10.1093/humrep/deag142 · Human clinical research

  4. Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol.

    BJU international · August 14, 2026 · Observational human study · cited 2 times · open access

    PMID 42598911 · DOI 10.1111/bju.70421 · Human clinical research

  5. Pubertal Triptorelin Exposure Alters Hypothalamic Reproductive-Metabolic Integration in a Sex-Specific Manner.

    Biology · August 12, 2026 · Animal study · cited 0 times · open access

    PMID 42651681 · DOI 10.3390/biology15161376 · Animal studies

  6. Development of a parsimonious predictive model for height gain outcome in children with central precocious puberty following gonadotropin-releasing hormone agonist therapy.

    Translational pediatrics · July 27, 2026 · Observational human study · cited 0 times · open access

    PMID 42592010 · DOI 10.21037/tp-2026-0254 · Human clinical research

  7. Central Precocious Puberty and Sjogren-Larsson Syndrome in a Child: A Rare Case Report.

    Clinical, cosmetic and investigational dermatology · July 21, 2026 · Case report · cited 0 times · open access

    PMID 42502351 · DOI 10.2147/ccid.s594107 · Human clinical research

  8. Efficacy of 24-weekly vs 12-weekly decapeptyl SR treatment in central precocious puberty: a UK multicentre retrospective cohort study.

    The Journal of clinical endocrinology and metabolism · July 1, 2026 · Observational human study · cited 1 times · open access

    PMID 41793064 · DOI 10.1210/clinem/dgag096 · Human clinical research

  9. In vitro fertilization-frozen embryo transfer in a patient with gonadotroph adenoma: Exacerbation of ovarian hyperstimulation by triptorelin: a case report.

    Journal of medical case reports · June 25, 2026 · Case report · cited 0 times · open access

    PMID 42351311 · DOI 10.1186/s13256-026-06230-5 · Human clinical research

  10. Sterile abscesses during GnRH agonist therapy for central precocious puberty: a case series and literature review.

    Journal of pediatric endocrinology & metabolism : JPEM · June 24, 2026 · Case report · cited 0 times · open access

    PMID 42333572 · DOI 10.1515/jpem-2026-0250 · Human clinical research

Browse all 1,670 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Arvekap; Decapeptyl; Diferelin; Moapar; Trellasar; Trelstar; Triptodur; Triptorelin; Triptoreline

((TITLE_ABS:"Arvekap" OR CHEM:"Arvekap") OR (TITLE_ABS:"Decapeptyl" OR CHEM:"Decapeptyl") OR (TITLE_ABS:"Diferelin" OR CHEM:"Diferelin") OR (TITLE_ABS:"Moapar" OR CHEM:"Moapar") OR (TITLE_ABS:"Trellasar" OR CHEM:"Trellasar") OR (TITLE_ABS:"Trelstar" OR CHEM:"Trelstar") OR (TITLE_ABS:"Triptodur" OR CHEM:"Triptodur") OR (TITLE_ABS:"Triptorelin" OR CHEM:"Triptorelin") OR (TITLE_ABS:"Triptoreline" OR CHEM:"Triptoreline")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 2). Triptorelin research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://bestpeptidecalculator.app/research/peptides/triptorelin